{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:11:17Z","timestamp":1775193077061,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1124\/jpet.115.230730","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T01:28:47Z","timestamp":1453858127000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fasiglifam\/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas"],"prefix":"10.1016","volume":"357","author":[{"given":"Ryo","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Tsujihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.230730_bib1","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/sj.bjp.0702731","article-title":"Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content","volume":"127","author":"Anello","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.230730_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lfs.2009.04.024","article-title":"A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure","volume":"85","author":"Asakawa","year":"2009","journal-title":"Life Sci"},{"key":"10.1124\/jpet.115.230730_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2007.00811.x","article-title":"Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats","volume":"10","author":"Atkinson","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 3","key":"10.1124\/jpet.115.230730_bib4","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.2337\/diabetes.53.suppl_3.S205","article-title":"Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib5","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.230730_bib6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1124\/jpet.115.230730_bib7","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1002\/dmrr.278","article-title":"Oral combination therapy for type 2 diabetes","volume":"18","author":"Charpentier","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1124\/jpet.115.230730_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0026-0495(76)90160-8","article-title":"Effects of reduced ATP concent on hepatic responses to glucagon","volume":"25","author":"DeRubertis","year":"1976","journal-title":"Metabolism"},{"key":"10.1124\/jpet.115.230730_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.115.230730_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1210\/en.2005-0225","article-title":"Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids","volume":"147","author":"Feng","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.115.230730_bib11","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","article-title":"Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV","volume":"50","author":"Feng","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.230730_bib12","doi-asserted-by":"crossref","first-page":"E670","DOI":"10.1152\/ajpendo.00035.2005","article-title":"Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release","volume":"289","author":"Fujiwara","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.115.230730_bib13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.neuropharm.2008.08.008","article-title":"Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization","volume":"55","author":"Gjoni","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.115.230730_bib14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2337\/diabetes.50.11.2481","article-title":"Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats","volume":"50","author":"Harmon","year":"2001","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1677\/joe.0.1650281","article-title":"Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide","volume":"165","author":"Hinke","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1124\/jpet.115.230730_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bph.12297","article-title":"TAK-875, a GPR40\/FFAR1 agonist, in combination with metformin prevents progression of diabetes and \u03b2-cell dysfunction in Zucker diabetic fatty rats","volume":"170","author":"Ito","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.230730_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1124\/jpet.115.230730_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2337\/dc12-0872","article-title":"Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes","volume":"36","author":"Kaku","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.115.230730_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.115.230730_bib20","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2337\/diabetes.48.10.2001","article-title":"Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity","volume":"48","author":"Kawaki","year":"1999","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib21","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.2337\/db08-0553","article-title":"The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding","volume":"57","author":"Kebede","year":"2008","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0006-291X(02)03064-4","article-title":"A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs","volume":"301","author":"Kotarsky","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.115.230730_bib23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2337\/db06-1532","article-title":"GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo","volume":"56","author":"Latour","year":"2007","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.arcmed.2005.01.003","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"36","author":"Leahy","year":"2005","journal-title":"Arch Med Res"},{"key":"10.1124\/jpet.115.230730_bib25","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1073\/pnas.91.23.10878","article-title":"Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships","volume":"91","author":"Lee","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.230730_bib26","doi-asserted-by":"crossref","first-page":"e27270","DOI":"10.1371\/journal.pone.0027270","article-title":"AMG 837: a novel GPR40\/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/jpet.115.230730_bib27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/dom.12442","article-title":"GPR40 agonists for the treatment of type 2 diabetes: life after \u2018TAKing\u2019 a hit","volume":"17","author":"Mancini","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.115.230730_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W","article-title":"UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years","volume":"15","author":"Matthews","year":"1998","journal-title":"Diabet Med"},{"key":"10.1124\/jpet.115.230730_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.2009.00145.x","article-title":"Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db\/db mice","volume":"157","author":"Moritoh","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.230730_bib30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/db08-1233","article-title":"Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice","volume":"58","author":"Nagasumi","year":"2009","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0091270011409230","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers","volume":"52","author":"Naik","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.115.230730_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.115.230730_bib33","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1021\/jm300170m","article-title":"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40\/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent","volume":"55","author":"Negoro","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.230730_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/endo.143.2.8623","article-title":"Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity","volume":"143","author":"Poitout","year":"2002","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.115.230730_bib35","first-page":"61","article-title":"The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin","volume":"15","author":"Portha","year":"1989","journal-title":"Diabete Metab"},{"key":"10.1124\/jpet.115.230730_bib36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","article-title":"The role of sulphonylureas in the management of type 2 diabetes mellitus","volume":"64","author":"Rendell","year":"2004","journal-title":"Drugs"},{"key":"10.1124\/jpet.115.230730_bib37","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0006-2952(02)00996-6","article-title":"Desensitization of insulin secretion","volume":"63","author":"Rustenbeck","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/jpet.115.230730_bib38","first-page":"A574","article-title":"The individual roles of inositol triphosphate and diacylglycerol, downstream messengers of FFAR1\/GPR40 produced by fasiglifam on the glucose-dependent insulinotropic effect","volume":"64","author":"Sakuma","year":"2015","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbrc.2005.07.042","article-title":"Role of GPR40 in fatty acid action on the beta cell line INS-1E","volume":"335","author":"Shapiro","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.115.230730_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature13494","article-title":"High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875","volume":"513","author":"Srivastava","year":"2014","journal-title":"Nature"},{"key":"10.1124\/jpet.115.230730_bib41","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/db08-0130","article-title":"Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice","volume":"57","author":"Tan","year":"2008","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib42","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2337\/diab.44.12.1447","article-title":"Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat","volume":"44","author":"Tokuyama","year":"1995","journal-title":"Diabetes"},{"key":"10.1124\/jpet.115.230730_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.183772","article-title":"TAK-875, an orally available G protein-coupled receptor 40\/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats","volume":"339","author":"Tsujihata","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.230730_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.115.230730_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pharmthera.2007.08.002","article-title":"G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes","volume":"116","author":"Winzell","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.115.230730_bib46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jdi.12229","article-title":"Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?","volume":"5","author":"Yabe","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1124\/jpet.115.230730_bib47","doi-asserted-by":"crossref","first-page":"e76280","DOI":"10.1371\/journal.pone.0076280","article-title":"A novel antidiabetic drug, fasiglifam\/TAK-875, acts as an ago-allosteric modulator of FFAR1","volume":"8","author":"Yabuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/jpet.115.230730_bib48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mce.2009.09.033","article-title":"Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells","volume":"315","author":"Yang","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.115.230730_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0167-0115(93)90137-W","article-title":"Influence of glucagon-like peptide-1 on beta cell responsiveness","volume":"44","author":"Zawalich","year":"1993","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.115.230730_bib50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1677\/JOE-08-0105","article-title":"Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway","volume":"198","author":"Zhao","year":"2008","journal-title":"J Endocrinol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.230730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:43:47Z","timestamp":1739994227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524192816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0022356524192816"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.230730","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fasiglifam\/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.230730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}